Hints and tips:
Related Special Reports
...GHO’s decision to put the Porto-based contract research organisation up for sale followed bidder interest, the people said, and comes amid an accelerating shift towards outsourcing in the pharmaceutical...
...The Development Bank of Japan said it wanted to connect the country’s start-ups with others across the world....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...The results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions....
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...Over the past year or so, the rapid development of artificial intelligence has sparked trepidation over how it may disrupt various facets of the modern world — from job security to the development of new...
...In October, pharmaceuticals companies Eisai and Eli Lilly unveiled research showing the benefits of using new Alzheimer’s drugs very early in the development of the disease....
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
...Pharmaceuticals companies are using AI to identify new molecules as targets for possible anticancer drugs....
...IDA’s Lohan warned of erecting new “barriers within the research and development cycle of new treatments” and possibly delaying market access....
...Wegovy, alongside Eli Lilly’s tirzepatide-based drugs, which are both administered via weekly injections, are expected to generate $18.2bn in global sales this year, according to projections by research...
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
...Dr Matthew Hobbs, director of research at Prostate Cancer UK, said such changes had “made the process safer and more accurate” but better evidence was needed to understand their full impact....
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
International Edition